Perspective Therapeutics logo

Perspective TherapeuticsNYSE: CATX

Profile

Sector:

Healthcare

Country:

United States

IPO:

10 November 2005

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$460.95 M
-57%vs. 3y high
64%vs. sector
-vs. 3y high
-vs. sector
-77%vs. 3y high
47%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 00:06:48 GMT
$6.82-$0.16(-2.29%)

Dividend

No data over the past 3 years
$151.33 K$232.76 K

Analysts recommendations

Institutional Ownership

CATX Latest News

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
globenewswire.com23 October 2024 Sentiment: POSITIVE

SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company's radiopharmaceutical programs being presented at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM") held in Hamburg, Germany, from October 19-23, 2024.

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
globenewswire.com16 October 2024 Sentiment: POSITIVE

SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from its second manufacturing facility for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals.

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
globenewswire.com11 October 2024 Sentiment: POSITIVE

SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 are being presented at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
globenewswire.com10 October 2024 Sentiment: POSITIVE

SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept
seekingalpha.com02 October 2024 Sentiment: POSITIVE

Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of 2024. The global melanoma market is expected to grow to $13.11 billion by 2029. Clinical supply agreement made with Bristol-Myers Squibb for use of Opdivo as a checkpoint inhibitor to be combined with VMT-01 to target patients with MC1R-positive metastatic melanoma.

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2
gurufocus.com02 October 2024 Sentiment: POSITIVE

Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close of $12.63.

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
globenewswire.com28 August 2024 Sentiment: POSITIVE

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
globenewswire.com30 July 2024 Sentiment: POSITIVE

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as noted.

3 Outperforming Stocks Surpassing Even Nvidia This Year
investorplace.com25 July 2024 Sentiment: POSITIVE

Nvidia (NASDAQ: NVDA ) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%.

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
globenewswire.com22 July 2024 Sentiment: POSITIVE

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes.  The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

  • 1(current)

What type of business is Perspective Therapeutics?

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

What sector is Perspective Therapeutics in?

Perspective Therapeutics is in the Healthcare sector

What industry is Perspective Therapeutics in?

Perspective Therapeutics is in the Medical Devices industry

What country is Perspective Therapeutics from?

Perspective Therapeutics is headquartered in United States

When did Perspective Therapeutics go public?

Perspective Therapeutics initial public offering (IPO) was on 10 November 2005

What is Perspective Therapeutics website?

https://www.perspectivetherapeutics.com

Is Perspective Therapeutics in the S&P 500?

No, Perspective Therapeutics is not included in the S&P 500 index

Is Perspective Therapeutics in the NASDAQ 100?

No, Perspective Therapeutics is not included in the NASDAQ 100 index

Is Perspective Therapeutics in the Dow Jones?

No, Perspective Therapeutics is not included in the Dow Jones index

When was Perspective Therapeutics the previous earnings report?

No data

When does Perspective Therapeutics earnings report?

The next expected earnings date for Perspective Therapeutics is 28 March 2025